Optimal Care Pathways Steering Committee

Cancer Australia Cancer Council Victoria Cancer Institute New South Wales Consumer representatives Department of Health and Human Services, Cancer Strategy and Development Monash University North Eastern Melbourne Integrated Cancer Service Olivia Newton-John Cancer Wellness and Research Centre Peter MacCallum Cancer Centre The University of Melbourne Wyong Hospital

Read More

Expert working group

Prof. Peter Choong (Chair), Surgeon, Peter MacCallum Cancer Centre Mr Naveed Alam, Thoracic Surgeon, St Vincent’s Hospital Lauren Atkins, Dietitian, Peter MacCallum Cancer Centre Dr Susie Bae, Medical Oncologist, Peter MacCallum Cancer Centre Victoria Bartlett, Orthotist/Prothetist, St Vincent’s Hospital Mandy Basson, Consumer representative, Sock it to Sarcoma!, Western Australia Prof. Richard Carey-Smith, Surgeon, Perth Orthopaedic…

Read More

Medical colleges and peak organisations invited to provide feedback

Allied Health Professions Australia Australian and New Zealand Society of Palliative Care Australian Chapter of Palliative Medicine, Royal Australasian College of Physicians Australian College of Nursing Australian Institute of Radiography Australian Medical Association Australian Orthopaedic Association Australasian Sarcoma Study Group Medical Oncology Group of Australia Royal Australasian College of Physicians Royal Australasian College of Surgeons…

Read More

Contributors and reviewers

Our thanks to the following health professionals, consumer representatives, stakeholders and organisations consulted in the development of this optimal cancer care pathway.

Read More

6.1 Signs and symptoms of recurrent, residual or metastatic disease

Between 30 and 40 per cent of all patients with sarcomas develop local or distant recurrence (Cancer Council Australia Sarcoma Guidelines Working Party 2014). The risk of recurrence is greatest in the first few years, with approximately two out of three recurrences developing within two years and 95 per cent by five years (of initial…

Read More

7.2 Research and clinical trials

All patients with sarcoma should be offered the opportunity to participate in a clinical trial or clinical research if appropriate (Field et al. 2013). Cross-referral between clinical trials centres should be encouraged to facilitate participation. Australasian Sarcoma Study Group is a national cooperative cancer clinical research group. It coordinates large-scale multi-centred sarcoma trials. Australian Cancer…

Read More

Statement of acknowledgement

We acknowledge the Traditional Owners of Country throughout Australia and their continuing connection to the land, sea and community. We pay our respects to them and their cultures and to Elders past, present and emerging. This work is available from the Cancer Council website. First published in January 2020. ISBN: 978 1 76096 154 1…

Read More

5.3 Research and clinical trials

All patients with sarcoma should be offered the opportunity to participate in a clinical trial or clinical research if appropriate (Field et al. 2013). Cross-referral between clinical trials centres should be encouraged to facilitate participation. Australasian Sarcoma Study Group is a national cooperative cancer clinical research group. It coordinates large-scale multi-centred sarcoma trials. Australian Cancer…

Read More

Appendix A: Supportive care

Supportive care in cancer refers to the following five domains: physical domain, which includes a wide range of physical symptoms that may be acute, relatively short-lived or ongoing, requiring continuing interventions or rehabilitation (NBCC & NCCI 2003) psychological domain, which includes a range of issues related to the person’s mental health and personal relationships (NBCC…

Read More